Evidence map›Paper›PMID 34027053›Full record

ArticleAcademic pathology

All Hands-On Deck and All Decks on Hand: Surmounting Supply Chain Limitations During the COVID-19 Pandemic.

Jill S Warrington, Jessica W Crothers, Andrew Goodwin, Linda Coulombe, Tania Hong, Lynn Bryan, Christina Wojewoda, Mark Fung, Gregory Warrington, Vanessa Clark and 2 more

Abstract read
In one paragraph

Article in Academic pathology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jill S WarringtonDepartment of Pathology and Laboratory Medicine, University of Vermont Medical Center, Robert Larner College of Medicine, Burlington, VT, USA.ORCID https://orcid.org/0000-0002-2196-1789
Jessica W CrothersDepartment of Pathology and Laboratory Medicine, University of Vermont Medical Center, Robert Larner College of Medicine, Burlington, VT, USA.
Andrew GoodwinDepartment of Pathology and Laboratory Medicine, University of Vermont Medical Center, Robert Larner College of Medicine, Burlington, VT, USA.
Linda CoulombeUniversity of Vermont Health Network, Supply Chain Department, Burlington, VT, USA.
Tania HongDepartment of Pathology and Laboratory Medicine, University of Vermont Medical Center, Robert Larner College of Medicine, Burlington, VT, USA.
Lynn BryanDepartment of Pathology and Laboratory Medicine, University of Vermont Medical Center, Robert Larner College of Medicine, Burlington, VT, USA.
Christina WojewodaDepartment of Pathology and Laboratory Medicine, University of Vermont Medical Center, Robert Larner College of Medicine, Burlington, VT, USA.
Mark FungDepartment of Pathology and Laboratory Medicine, University of Vermont Medical Center, Robert Larner College of Medicine, Burlington, VT, USA.
Gregory WarringtonUniversity of Vermont, Mathematics and Statistics, Burlington, VT, USA.
Vanessa ClarkAspenti Health, South Burlington, VT, USA.
Lauren RisleyAspenti Health, South Burlington, VT, USA.
Michael LewisDepartment of Pathology and Laboratory Medicine, University of Vermont Medical Center, Robert Larner College of Medicine, Burlington, VT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Testing during the COVID-19 pandemic has been crucial to public health surveillance and clinical care. Supply chain constraints-spanning limitations in testing kits, reagents, pipet tips, and swabs availability-have challenged the ability to scale COVID-19 testing. During the early months, sample collection kits shortages constrained planned testing expansions. In response, the University of Vermont Medical Center, University of Vermont College of Medicine, Vermont Department of Health Laboratory, Aspenti Health, and providers across Vermont including 16 area hospitals partnered to surmount these barriers. The primary objectives were to increase supply availability and manage utilization. Within the first month of Vermont's stay-at-home order, the University of Vermont Medical Center laboratory partnered with College of Medicine to create in-house collection kits, producing 5000 per week. University of Vermont Medical Center reassigned 4 phlebotomists, laboratory educators, and other laboratory staff, who had reduced workloads, to participate (requiring a total of 5.3-7.6 full-time equivalent (FTE) during the period of study). By August, automation at a local commercial laboratory produced 22,000 vials of media in one week (reducing the required personnel by 1.2 FTE). A multisite, cross-institutional approach was used to manage specimen collection kit utilization across Vermont. Hospital laboratory directors, managers, and providers agreed to order only as needed to avoid supply stockpiles and supported operational constraints through ongoing validations and kit assembly. Throughout this pandemic, Vermont has ranked highly in number of tests per million people, demonstrating the value of local collaboration to surmount obstacles during disease outbreaks and the importance of creative allocation of resources to address statewide needs.

Indexed as

COVID-19inventory managementpandemicspecimen collection kitssupply chain

Identifiers

PMID34027053
PMCPMC8120534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.